Table 1. Baseline Characteristics, Patients Who Received Placebo First Compared to Those That Received Pitavastatin First.
| Characteristics | Placebo(n = 12) | Pitavastatin(n = 12) |
|---|---|---|
| Age, years* | 46.7 (6.8) | 49.6 (10.6) |
| Sex, n (%) | ||
| Male | 6 (50) | 8 (66.7) |
| Female | 6 (50) | 4 (33.3) |
| Body mass index, kg/m2* | 22.5 (3.4) | 23.8 (2.7) |
| Underlying conditions, n (%) | ||
| No | 8 (66.7) | 4 (33.3) |
| Dyslipidemia | 2 (16.7) | 4 (33.3) |
| Chronic hepatitis B and C virus infection | 2 (16.7) | 2 (16.7) |
| Others | 0 (0) | 2 (16.7) |
| Cardiovascular risk factors, n (%)$ | ||
| <2 | 11 (91.7) | 7 (58.3) |
| ≥2 | 1 (8.3) | 5 (41.7) |
| Baseline creatinine, mg/dL* | 0.9 (0.2) | 0.9 (0.2) |
| Baseline FBS, mg/dL* | 97.1 (10.5) | 100.8 (10.1) |
| Baseline CD4 cell counts, cells/mm3* | 718.1 (181.2) | 641.9 (196.5) |
| HIV RNA <40 copies/mL, n (%) | 11 (91.7) | 12 (100) |
| Duration of ATV/r use, months# | 36 (24–36) | 42 (30–54) |
| ARV regimens combined with ATV/r, n (%) | ||
| TDF + FTC/3TC | 6 (50) | 5 (41.7) |
| TDF + other NRTIs (exclude 3TC/FTC) | 2 (16.7) | 2 (16.7) |
| No TDF in backbone | 4 (33.3) | 5 (41.7) |
*Mean (SD),
$current smoking, systolic blood pressure ≥140 mmHg or on antihypertensive drugs, HDL <40 mg/dL, first-degree relative <55 years in male and <65 years in female, and age >45 years in male or >55 years in female,
#median (IQR)
3TC: lamivudine, ARV: antiretroviral, ATV/r: atazanavir/ritonavir, FBS: fasting blood sugar, FTC: emtricitabine, IQR: interquartile range, SD: standard deviation, TDF: tenofovir disoproxil fumarate.